Vor BioPharma, Inc. logo

Vor BioPharma, Inc.

Vor BioPharma is an immuno-oncology company dedicated to developing a new class of targeted cell therapies to treat highly fatal malignancies. The company is advancing a novel approach to chimeric antigen receptor (CAR) T-cell therapy that has the potential to broaden its applicability and success rate in other cancers.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.vorbiopharma.com
Founded
Disease Focus
Development Stage
STOCK CODENon Listed
Address
501 Boylston Street. Suite 6102., MA 02116
Boston
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In Feb 2019, Vor Biopharma received $42Mn in Series A financing round led by 5AM Ventures and RA Capital Management. Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research (NIBR) and some others.